Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Liam Smyth, MD FRCPath, Rena Buckstein, MD FRCPC, Pennell Nancy, BSc, Rashmi Weerasinghe, Matthew Cheung, MD MS, FRCP, Eugenia Piliotis, MD FRCP, MD, Kevin Imrie, MD, David Spaner, MD PhD, Marciano D. Reis, MD, Lisa Chodirker, MD, Zeina Ghorab, Violet ruth,nancy Milliken, Angela Boudreau, RN, BScN, MN, CON(C), Neil Berinstein, MD

Blood (2017) 130 (Supplement 1): 4069.

https://doi.org/10.1182/blood.V130.Suppl_1.4069.4069

Published: 2017

Journal Articles

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

Neil L Berinstein, MD, Nancy M Pennell, BSc, Rashmi Weerasinghe, Matthew C. Cheung, MD SM, FRCPC, Eugenia Piliotis, MD FRCP, MD, Kevin R Imrie, MD, Mary-Anne Cussen, Rena Buckstein, MD, Zeina Ghorab, Ellen Miles, Marciano D. Reis, MD

Blood (2016) 128 (22): 1794.

https://doi.org/10.1182/blood.V128.22.1794.1794

Published: 2016

Journal Articles

Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab

Neil L Berinstein, MD, FRCPC, Nancy M Pennell, B Sc, Mary-Anne Cussen, RN, BScN, CCRP, Kevin R Imrie, MD, Eugenia Piliotis, MD, FRCPC, Rena Buckstein, MD, Zeina Ghorab, MD, Ellen Anne Miles, MSc, Alden E. Chesney, MD, Matthew Cheung, MD

Blood (2012) 120 (21): 3681.

https://doi.org/10.1182/blood.V120.21.3681.3681

Published: 2012

Journal Articles

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

Nancy M Pennell, B Sc, Matthew Cheung, MD, MS, FRCP, Lisa K Hicks, MD, MSc, FRCPC, Eugenia Piliotis, MD, FRCPC, Kevin R Imrie, MD, Rena Buckstein, MD, FRCPC, Cindy Davidson, RN, Mary-Anne Cussen, RN, BScN, CCRP, Zeina Ghorab, MD, Alden Chesney, MD, FRCPC, Neil L Berinstein, MD, FRCPC

Blood (2011) 118 (21): 2701.

https://doi.org/10.1182/blood.V118.21.2701.2701

Published: 2011

Journal Articles

Hypogammaglobulinemia Following Rituximab and High-Dose Therapy and Autologous Stem-Cell Transplant: Incidence and Predictors of Prolonged Immunoglobulin Deficiencies

Nancy Pennell, Matthew Cheung, MD SM, FRCP, Lisa K Hicks, MD, MSc, Rena Buckstein, MD, FRCPC, Kevin R Imrie, MD, Eugenia Piliotis, MD, David Spaner, Zeina Ghorab, Marciano D. Reis, MD, Violet Milliken, Angela Boudreau, Neil Berinstein, MD

Blood (2008) 112 (11): 4351.

https://doi.org/10.1182/blood.V112.11.4351.4351

Published: 2008

Journal Articles

Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.

Lisa Hicks, Rena Buckstein, Joy Mangel, Eugenia Piliotis, Kevin Imrie, Matthew C. Cheung, David E. Spaner, Marciano D. Reis, Zeina Ghorab, Violet Milliken, Nancy Pennell, Neil Berinstein

Blood (2006) 108 (11): 3067.

https://doi.org/10.1182/blood.V108.11.3067.3067

Published: 2006

NARROW

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

Hypogammaglobulinemia Following Rituximab and High-Dose Therapy and Autologous Stem-Cell Transplant: Incidence and Predictors of Prolonged Immunoglobulin Deficiencies

Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

Hypogammaglobulinemia Following Rituximab and High-Dose Therapy and Autologous Stem-Cell Transplant: Incidence and Predictors of Prolonged Immunoglobulin Deficiencies

Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only